An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
|Articles|May 12, 2022
Daily OTC Pearl: BC Max Strength
Author(s)Saro Arakelians, PharmD
BC MAX Strength Fast Pain Relief Powders work fast to relieve tough headaches, body aches, aches and pains, and menstrual cramps.
Advertisement
OTC/Lifestyle Pearl of the Day: BC Max Strength
Indication: BC MAX Strength Fast Pain Relief Powders work fast to relieve tough headaches, body aches, aches and pains, and menstrual cramps.
Insight:
- BC MAX Strength Fast Pain Relief Powders contain 500 mg of aspirin and 500 mg of acetaminophen—the maximum level of pain reliever available OTC—in addition to 65 mg of caffeine.
- Directions: Do not take more than directed.
- Adults and children 12 years of age and over place 1 pack on tongue every 6 hours, while symptoms persist. Drink a full glass of water or other liquid.
Source:
Advertisement
Related to this article
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
3
Glucose Monitoring: Timing Makes Every Reading Count
4
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
5